Perfluorocarbon compounds as vehicles for pulmonary drug delivery.
Drug delivery to the diseased lung is hindered by the buildup of fluid and shunting of blood flow away from the site of injury. The use of perfluorocarbon compounds (PFCs) as drug delivery vehicles has been proposed to overcome these obstacles. This drug delivery approach is based on the unique properties of PFCs. For example, PFCs can homogeneously fill the lung and recruit airways by replacing edematous fluid. Analogously, drugs administered with a PFC vehicle are expected to be homogeneously distributed throughout the lung. At the same time, intrapulmonary administration of the drug will achieve higher drug concentrations in the lung than conventional approaches, while reducing systemic exposure. Unfortunately, PFCs are poor solvents for typical drug molecules. To overcome this obstacle, several approaches, such as dispersions, prodrugs, solubilizing agents and (micro)emulsions, are under investigation to develop homogeneous PFC-drug mixtures suitable for intrapulmonary administration.
Lehmler
Hans-Joachim
HJ
Research Scientist, University of Iowa, Department of Occupational and Environmental Health, Iowa City, IA 52242, USA. hans-joachim-lehmler@uiowa.edu
D000280:Administration, Inhalation; D000818:Animals; D005466:Fluorocarbons / Q000008:administration & dosage*; D015316:Genetic Therapy; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D014677:Pharmaceutical Vehicles / Q000008:administration & dosage*
D005466:Fluorocarbons; D004364:Pharmaceutical Preparations; D014677:Pharmaceutical Vehicles